Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growth. The Danish pharma ...

In its fourth-quarter results statement, Novo Nordisk said that it had started to increase the supply of starting doses for Wegovy in the US since the start of the year thanks to those investments ...

Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs ... which continues to surge in popularity. Novo Nordisk has been slowly increasing production capacity ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Employers and employees spent more than $400 billion on obesity care in 2023; Novo Nordisk's CEO said weight ... pay $25 or less for a month's supply. Business Group on Health recently surveyed ...

Update: Adds company statement about Ozempic availability in the U.S. Novo Nordisk (NVO) has said in a note published by the European Medicines Agency that the supply shortage of its diabetes drug ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to ...